Twist Bioscience (NASDAQ:TWST) CEO Sells 4,548 Shares of Stock

Twist Bioscience Corporation (NASDAQ:TWST) CEO Emily Leproust sold 4,548 shares of the company’s stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $202.15, for a total transaction of $919,378.20. Following the completion of the sale, the chief executive officer owned 562,760 shares in the company, valued at approximately $113,761,934. This trade represents a 0.80% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Twist Bioscience Stock Down 6.8%

NASDAQ:TWST traded down $11.32 during mid-day trading on Wednesday, reaching $155.65. The stock had a trading volume of 5,641,331 shares, compared to its average volume of 1,679,962. The company has a market capitalization of $9.76 billion, a price-to-earnings ratio of -70.11 and a beta of 2.19. Twist Bioscience Corporation has a 1-year low of $23.30 and a 1-year high of $219.71. The stock’s 50 day simple moving average is $140.34 and its two-hundred day simple moving average is $94.39. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The firm had revenue of $118.38 million for the quarter, compared to analyst estimates of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The company’s quarterly revenue was up 23.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.33 EPS. Equities analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Western Wealth Management LLC acquired a new stake in shares of Twist Bioscience in the first quarter valued at approximately $31,000. Strs Ohio acquired a new position in shares of Twist Bioscience during the first quarter worth approximately $33,000. Strategic Advocates LLC boosted its position in shares of Twist Bioscience by 562.7% during the fourth quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock worth $34,000 after buying an additional 906 shares during the period. PNC Financial Services Group Inc. grew its holdings in Twist Bioscience by 89.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock worth $46,000 after buying an additional 453 shares in the last quarter. Finally, Fifth Third Bancorp bought a new position in Twist Bioscience in the 1st quarter worth approximately $54,000.

Analyst Upgrades and Downgrades

TWST has been the topic of a number of research reports. Canaccord Genuity Group increased their target price on shares of Twist Bioscience from $90.00 to $120.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, September 21st. Evercore lowered shares of Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price objective on the stock. in a research note on Monday, July 6th. Leerink Partners raised their target price on shares of Twist Bioscience from $160.00 to $190.00 and gave the stock an “outperform” rating in a report on Tuesday, September 29th. Finally, Piper Sandler lifted their target price on Twist Bioscience from $85.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, August 5th. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $126.18.

Twist Bioscience Company Profile

Twist Bioscience Corporation (NASDAQ:TWST) is a biotechnology company that develops and manufactures synthetic DNA using a silicon-based production platform. Its technology is designed to enable the precise, high-throughput synthesis of DNA at smaller scale and with potentially lower material consumption than traditional methods.

The company provides synthetic DNA products and services for applications in drug discovery and development, biotechnology research, agriculture, industrial chemicals and other life sciences markets.